3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Melanoma
7
Carcinoma, Renal Cell
4
Squamous Cell Carcinoma of Head and Neck
3
Neoplasm Metastasis
3
Urinary Bladder Neoplasms
2
Triple Negative Breast Neoplasms
2
Recurrence
2
Lymphoma, Non-Hodgkin
2
Colorectal Neoplasms
2
Carcinoma, Transitional Cell
2
Carcinoma, Non-Small-Cell Lung
2
Unspecified Adult Solid Tumor, Protocol Specific
1
Stomach Neoplasms
1
Skin Neoplasms
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Neuroblastoma
1
Neoplasms
1
Medulloblastoma
1
Lymphoma
1
Leukemia, B-Cell
1
Leukemia
1
Kidney Neoplasms
1
Head and Neck Neoplasms
1
Glioma
1
Ependymoma
1
Carcinoma, Merkel Cell
1
Advanced Cancer
1
Interventions
Doxorubicin
33
pembrolizumab
16
Gemcitabine
15
eribulin
10
Irinotecan
10
olaratumab
9
Trabectedin
9
pazopanib
8
Docetaxel
8
Injections
7
Cyclophosphamide
7
Nivolumab
6
Fluorouracil
6
anlotinib
5
Temozolomide
5
Ipilimumab
5
Ifosfamide
5
Bevacizumab
5
tazemetostat
4
ridaforolimus
4
Drug Therapy
4
Cetuximab
4
Carboplatin
4
toripalimab
3
surufatinib
3
spartalizumab
3
ganitumab
3
entrectinib
3
conatumumab
3
belinostat
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Sarcoma
×
bempegaldesleukin
×
Clear all
NCT03435640
2023-03-08
REVEAL
Nektar Therapeutics
Phase 1/2
Terminated
64 enrolled
22 charts